News | January 05, 2015

InspireMD Announces Clinical Data from MASTER and CARENET Trials

Master II data reveals statistically significant mortality benefit with MGuard stent; CARENET showed no major adverse cardiac events after 30 days with CGuard system

InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials

MGuard image courtesy of InspireMD

January 5, 2015 — InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major cardiology congress in Israel in December. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next-generation MGuard drug eluting stent (DES) platform. The company also announced ipsilateral diffusion weighted magnetic resonance imaging (DW-MRI) results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.

MASTER II was a global clinical trial conducted under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) and was intended for U.S. registration of the MGuard Prime coronary EPS for use in patients presenting with ST-segment elevated myocardial infarction (STEMI). The MASTER II trial was designed to show superiority of ST segment resolution 60-90 minutes post procedure as well non-inferiority in all-cause death or recurrent target vessel myocardial infarction. While the trial was halted well short of the planned enrollment, the company elected to unblind the data and present the results on behalf of the study investigators. 

Gregg Stone, M.D., professor of medicine at Columbia University and principal investigator of the trial, presented 30-day results on the 310 patients enrolled in MASTER II as well as pooled data from MASTER II and the 433-patient MASTER I trial completed and published in 2012. While in MASTER I, the primary endpoint of superiority in ST-segment resolution was achieved (57.8 percent vs. 44.7 percent, p=0.008), MASTER II did not show a difference in ST-segment resolution between MGuard and control stents (FDA-approved bare metal or drug eluting stents) 56.9 percent vs. 59.3 percent (p=0.68). Pooled data between MASTER I and MASTER II for ST resolution continued to favor MGuard 57.5 percent vs. 50.7 percent for control (p=0.07).

Impressively, 30-day mortality results for the MGuard in the MASTER II trial remained low (0.6 percent vs. 1.9 percent, p=0.62), consistent with all previous MGuard trials and registries and overall MACE (major adverse cardiac events) was favorable for MGuard (2.6 percent vs. 4.5 percent p=0.36). Pooled mortality data for MASTER I and II showed a statistically significant reduction in mortality with MGuard (0.3 percent vs. 1.9 percent, p=0.04). Infarct size, another important indicator of mortality, showed a positive trend for MGuard in MASTER II (mean 22.60 percent vs. 27.48 percent, p=0.16), as well as in the pooled analysis (mean 18.80 percent vs. 22.24 percent, p=0.26). 

CARENET data was also presented by Piotr Musia?ek, Ph.D., co-principal investigator for the CARENET study, from Jagiellonian University Medical College at John Paul II Hospital, in Krakow, Poland. He reported new positive clinical data from the CGuard CARENET (CARotid Embolic protection study using microNET) trial. The CARENET trial recruited a total of 30 patients and showed exceptional safety and efficacy with 0 percent MACCE (meaning no death, stroke or myocardial infarction) at 30 days, substantially lower than in other carotid stenting trials. Additionally, the incidence of new ischemic ipsilateral lesions as assessed by DW-MRI after carotid artery stenting was 37 percent, a reduction of approximately 50 percent when compared to published historical control groups of non-mesh covered carotid stents.The CARENET trial also reported an average lesion volume per patient that was 10 times smaller than historical control groups. The reduction in both the incidence and volume of new ischemic lesions indicates therapeutic benefits of the MicroNet technology and that the benefits of using this device may extend beyond the acute procedural period.

For more information: www.inspiremd.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init